moneyheap
DHR · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Danaher Corporation (DHR) stock moving?
Danaher's most material recent fact is its Q3 2026 report: revenue rose 8.5% to $6.6B, adjusted EPS grew 11.5% to $2.11, and core revenue excluding respiratory rose 5.5%, with management calling the performance better than expected and pointing to accelerating core growth. Around that, news flow has been steady and product-driven: FDA clearances for Cepheid and Beckman Coulter assays (Nov 3), a CE mark for Cepheid's respiratory panel (Nov 10), and a research mRNA launch (Nov 4). Management also reiterated at the UBS conference that reshoring-related revenue should start in 2028. Negatives are the $8.7M of executive share sales disclosed Oct 30 and Evercore ISI's cut of its price target from $242 to $205 on Oct 28, which sits well below the current price. Price action over the last 30 days shows a range of about $223 to $238.5, with the stock at $236.11 on Nov 10, up about 3% from the Oct 22 close of $229.75 and recovering from a $225.86 low on Nov 5. That Nov 5 session had the largest volume in the window (5.14M shares), and the stock rebounded quickly, which points to buyers stepping in near $226 to $228. The $238 to $238.5 area, where highs were set on Oct 28, Oct 30 and Nov 5, has capped rallies so far. Volume on recent up days has been moderate, not a surge, so the rebound is not yet strongly confirmed by volume.
News behind the analysis
- Cepheid Receives CE Marking Under IVDR for Xpert Respiratory PanelCepheid, a Danaher company, received CE marking under the EU IVDR for its multiplex PCR test that detects 13 common respiratory pathogens. The approval widens the diagnostics portfolio's European reach.
- Danaher Outlines Growth Strategy at UBS Global Healthcare ConferenceDanaher detailed priorities on core growth, commercial execution and disciplined M&A, and expects reshoring-related revenue to begin in 2028. Management presented this at the UBS conference.
- Danaher Companies IDT and Aldevron Launch New mRNA Solutions for Gene EditingSubsidiaries IDT and Aldevron jointly launched research-grade mRNA products for base and prime editing workflows. The launch is a routine product extension in research tools.
- Cepheid Receives FDA Clearance for Xpert Hemorrhagic Fever PanelCepheid received U.S. FDA clearance for a multiplex PCR test that detects several viral hemorrhagic fever viruses from a single sample. The clearance expands its U.S. infectious disease menu.
- Beckman Coulter Diagnostics Receives FDA Clearance for Access MeMed BV® AssayBeckman Coulter Diagnostics received FDA clearance for a blood test that helps clinicians tell bacterial from viral infections, with results in as little as 15 minutes. The test adds to the U.S. diagnostics lineup.
- Danaher Executives Report Significant Stock SalesExecutives Matthew McGrew and Christopher Bouda disclosed share sales totaling over $8.7 million in SEC filings. Insider selling can weigh on sentiment, though it is not a fundamental signal on its own.
- Evercore ISI Adjusts Price Target on Danaher to $205 From $242Evercore ISI cut its price target on Danaher from $242 to $205. The new target sits about 13% below the Nov 10 close of $236.11.
- Danaher Reports Third Quarter 2026 ResultsNet earnings were $1.2B ($1.71 per diluted share, up 34.5%), revenue rose 8.5% to $6.6B, and non-GAAP adjusted EPS grew 11.5% to $2.11. Core revenue excluding respiratory rose 5.5%, and the company gave Q4 and full-year 2026 outlook.
About Danaher Corporation
Danaher is a Washington, D.C.-based conglomerate that sells instruments, consumables and software used in drug development, scientific research and clinical diagnostic testing. It is known for the Danaher Business System, its continuous-improvement management approach, and for growing through acquisitions. Brands include Cytiva, Pall, Beckman Coulter, Cepheid, Leica and SCIEX, and it recently added Masimo. Julie Sawyer Montgomery became CEO in October 2026.
How it makes money
Danaher reports three segments of roughly similar size: Biotechnology (bioprocessing equipment and consumables from Cytiva and Pall, used to make biologic drugs), Life Sciences (lab instruments, microscopes and genomics tools) and Diagnostics (clinical lab analyzers, Cepheid molecular tests and pathology). Each brought in close to $2 billion a quarter in mid-2026. Most sales are recurring consumables, reagents and service, not one-off instrument sales. Total revenue is about $6–6.6 billion a quarter, or roughly $25 billion a year.
What usually moves DHR
- Biopharma bioprocessing demand and spending cycles
- Respiratory testing volumes (COVID/flu) at Cepheid
- Biotech funding and pharma R&D budgets
- China demand and healthcare policy
- Acquisitions such as Masimo